FDA approves first automated blood draw robot for outpatient clinics

The FDA’s approval marks the first regulatory clearance for a fully automated blood-draw device intended for outpatient settings. The device, named Aletta, performs vein detection using near-infrared light and Doppler ultrasound and then carries out the steps of a blood draw, including tourniquet application, needle insertion and disposal, and bandage placement. A trained phlebotomist must begin the procedure and remain present to oversee the robot’s operation. This changes the workflow by shifting the manual venipuncture task to a supervised robotic process.

Adopting the system will require clinics to purchase the robotic units and train existing phlebotomy staff to act as supervisors rather than primary operators. Each supervisor can monitor up to three Aletta robots simultaneously, which could reduce the number of personnel needed per draw station. However, facilities must also budget for maintenance, calibration of the optical and ultrasound sensors, and integration with existing electronic health record or specimen tracking systems. No pricing or specific implementation timelines were disclosed in the source material.

The technology’s current limits are tied to the requirement that a qualified phlebotomist initiates each draw and remains present for oversight, meaning the robot does not operate fully autonomously. Performance data supporting the approval only demonstrate success rates comparable to or better than manual phlebotomy under the studied conditions, with no evidence provided for use in inpatient, emergency, or home-care settings. Additionally, the source notes that there is no announced date for when the devices will appear in doctors’ offices, indicating that widespread deployment remains uncertain.